This site is intended for healthcare professionals outside the US.

After VEGFR-TKI failure in aRCC,

AFINITOR offers an established safety profile1,2

Most common AEs (≥10%) from RECORD-12
Most common AEs and laboratory abnormalities (≥10% with AFINITOR)


  • In clinical studies and post-marketing spontaneous reports, everolimus has been associated with:
    • Serious cases of hepatitis B reactivation, including fatal outcome. Reactivation of infection is an expected event during periods of immunosuppression
    • Renal failure events (including fatal outcome) and proteinuria. Monitoring of renal function is recommended
    • Cases of amenorrhoea (secondary amenorrhoea and other menstrual irregularities)
  • In clinical trials and post-marketing spontaneous reports, angioedema has been reported with and without concomitant use of ACE inhibitors 
  • The most frequent Grade 3/4 adverse reactions (those with incidence >2%) were decreased lymphocytes, increased glucose, decreased hemoglobin, decreased phosphate, increased cholesterol, infections, stomatitis, fatigue and pnuemonitis1
*Adverse events, irrespective of relation to treatment, and laboratory abnormalities occurring in ≥10% of patients in the everolimus group.
  1. AFINITOR [summary of product characteristics]. Novartis Pharma AG; May 2016.
  2. Motzer RJ, Escudier B, Oudard S, et al; for the RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-4265.

Safety Information


Important note: Before prescribing, consult the full prescribing information. 

Presentation: ♦ Tablets containing 2.5 mg, 5 mg or 10 mg of everolimus. 

Indications: postmenopausal women with hormone receptor-positive advanced breast cancer (BC) in combination with an aromatase inhibitor after prior endocrine therapy; patients with advanced neuroendocrine tumors (NET) of gastrointestinal, lung or pancreatic origin; patients with advanced renal cell carcinoma (RCC).

Dosage and administration: ♦ 10 mg once daily. ♦The daily dose should be taken orally at the same time every day, either consistently with or consistently without food. ♦Dose modification: Dose interruption (with or without dose reduction) or discontinuation may be required to manage adverse drug reactions (ADRs). Dose modification may be required with concomitant use of moderate CYP3A4/PgP inhibitors or strong CYP3A4 inducers, hepatic impairment. ♦Pediatric patients: not recommended for use in children or adolescents. ♦Patients with hepatic impairment: recommended dose is 7.5 mg daily in patients with mild hepatic impairment (Child-Pugh A); 5 mg daily in patients with moderate hepatic impairment (Child-Pugh B); not recommended in patients with severe hepatic impairment (Child-Pugh C), unless the benefit outweighs the risk. In the latter case, a dose of 2.5 mg daily must not be exceeded. Dose adjustments should be made if a patient’s hepatic (Child-Pugh) status changes during treatment. ♦Missed Dose: AFINITOR can still be taken up to 6 hours after the time it is normally taken. After more than 6 hours, the dose should be skipped for that day. The next day, AFINITOR should be taken at its usual time. Double doses should not be taken to make up for the one that was missed.

Contraindications: Hypersensitivity to the active substance, to other rapamycin derivatives or to any of the excipients. 

Warnings/Precautions: ♦Non-infectious pneumonitis: Cases have been described in patients taking AFINITOR, some of these have been severe and on rare occasions, a fatal outcome was observed. A diagnosis of non-infectious pneumonitis should be considered in patients presenting with non-specific respiratory signs and symptoms such as hypoxia, pleural effusion, cough or dyspnea, and in whom infectious, neoplastic, and other non-medicinal causes have been excluded. Opportunistic infections such as pneumocystis jirovecii pneumonia (PJP) should be ruled out in the differential diagnosis of non-infectious pneumonitis. In some cases, management of pneumonitis may require interruption or discontinuation of treatment. The use of corticosteroids may be indicated. For patients who require use of corticosteroids for the treatment of non-infectious pneumonitis, prophylaxis for PJP may be considered. AFINITOR may be reinitiated at a lower dose. ♦Infections: AFINITOR has immunosuppressive properties. Localized and systemic bacterial, fungal, viral, or protozoal infections (e.g. pneumonia, aspergillosis, candidiasis, or PJP and hepatitis B reactivation) have been described in patients taking AFINITOR; some of these have been severe and occasionally fatal. Pre-existing infections should be resolved prior to starting treatment with AFINITOR. Be vigilant for symptoms or signs of infection during treatment with AFINITOR. In case of emergent infections, institute appropriate treatment promptly and consider interruption or discontinuation of AFINITOR. If a diagnosis of invasive systemic fungal infection is made, discontinue AFINITOR and treat with appropriate antifungal therapy. Prophylaxis for PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. ♦Hypersensitivity reactions have been observed with everolimus. ♦Angioedema: Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema (e.g. swelling of the airways or tongue, with or without respiratory impairment). ♦Stomatitis: Stomatitis is the most commonly reported ADR in patients treated with AFINITOR and mostly occurs within the first 8 weeks of treatment. Management may require temporary dose interruption, dose reduction or discontinuation. Topical treatments are recommended, but alcohol-, hydrogen peroxide, iodine-, or thyme containing mouthwashes should be avoided. ♦Renal failure events: Cases of renal failure (including acute renal failure), some fatal, have been observed in patients treated with AFINITOR. Renal function should be monitored particularly where patients have additional risk factors that may further impair their renal function. ♦Laboratory tests and monitoring: Monitoring of renal function, blood glucose, blood lipids, and complete blood counts is recommended prior to initiation of and periodically during treatment. ♦Interactions: Co-administration with strong CYP3A4/PgP inhibitors should be avoided. Use caution when co-administering with moderate CYP3A4/PgP inhibitors; monitor for adverse effects and consider a dose reduction. Co-administration with strong CYP3A4/PgP inducers should be avoided. If AFINITOR has to be co-administered with a strong CYP3A4/PgP inducer monitor for clinical response and consider a dose increase. Exercise caution when co-administering with oral CYP3A4 substrates with a narrow therapeutic index; monitor for adverse effects. ♦Hepatic impairment: Not recommended in patients with severe hepatic impairment (Child-Pugh C) unless the potential benefit outweighs the risk. ♦Vaccination: Avoid use of live vaccines and close contact with people who have received live vaccines. ♦Wound healing complications have been observed in patients taking AFINITOR. Caution should be exercised in the peri-surgical period.

Pregnancy, lactation, females and males of reproductive potential: ♦Pregnancy: AFINITOR should not be given to pregnant women unless the potential benefit outweighs the potential risk to the fetus. Male patients taking AFINITOR should not be prohibited from attempting to father children. ♦Lactation: Women taking AFINITOR should not breast-feed during treatment and for 2 weeks after the last dose.

Females and males of reproductive potential: ♦Contraception: Use highly effective contraception methods while receiving AFINITOR and for up to 8 weeks after ending treatment. ♦Infertility: Male and female fertility may be compromised by treatment with AFINITOR.

Interactions: See “Interactions” subsection of Warnings and Precautions. 

Adverse drug reactions: ♦Very common (≥10%): Infections, anaemia, decreased appetite, hyperglycaemia, hypercholesterolaemia, dysgeusia, headache, pneumonitis, epistaxis, cough, stomatitis, diarrhoea, nausea, rash, pruritus, fatigue, oedema peripheral, asthenia, weight decreased. ♦Common (≥1 to <10%): Thrombocytopenia, neutropenia, leukopenia, lymphopenia, hypertriglyceridaemia, hyperlipidaemia, hypophosphataemia, diabetes mellitus, hypokalaemia, dehydration, insomnia, hypertension, haemorrhage, dyspnoea, vomiting, dry mouth, abdominal pain, oral pain, dyspepsia, dysphagia, dry skin, nail disorder, erythema, acne, hand-foot syndrome, arthralgia, renal failure, proteinuria, menstruation irregular, pyrexia, mucosal inflammation, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, blood creatinine increased. ♦Uncommon (≥0.1 to <1%): Pancytopenia, hypersensitivity, ageusia, congestive cardiac failure, deep vein thrombosis, haemoptysis, pulmonary embolism, increased daytime urination, acute renal failure, amenorrhoea, non-cardiac chest pain, impaired wound healing. ♦Rare (<0.1%): Pure red cell aplasia, acute respiratory distress syndrome, angioedema.

Laboratory abnormalities:

♦Very common (≥10%): Haematology: haemoglobin decreased, lymphocytes decreased, white blood cells decreased, platelets decreased, neutrophils decreased (or collectively as pancytopenia). Clinical chemistry: glucose (fasting) increased, cholesterol increased, triglycerides increased, AST increased, phosphate decreased, ALT increased, creatinine increased, potassium decreased, albumin decreased.

Packs and prices: Country specific.

Legal classification: Country specific.